What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Difference Between mRNA and Non-mRNA Vaccines Explained

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to mRNA and Non-mRNA Vaccines

Vaccines function by presenting the immune system with a foreign antigen—typically a protein or glycoprotein from a pathogen—in a context that triggers a protective, memory-forming response. The fundamental distinction between mRNA and non-mRNA vaccines lies in where the antigen is produced. mRNA vaccines deliver a synthetic messenger RNA sequence that instructs the recipient's own cells to synthesize the antigen intracellularly. Non-mRNA vaccines, by contrast, deliver the antigen itself (or a viral vector encoding it) directly, bypassing the need for host-cell translation of exogenous genetic material.

This difference is not merely technical; it shapes every downstream property of the vaccine: the composition of the formulation, the delivery vehicle, the route of antigen presentation, the type of immune response generated, the cold-chain requirements, the speed of manufacturing, and the safety profile. Understanding this distinction requires a mechanistic grasp of both platforms, which this article provides.

Mechanism of mRNA Vaccines

mRNA Delivery Systems

mRNA is an inherently unstable molecule. Bare RNA is rapidly degraded by ubiquitous ribonucleases (RNases) in the extracellular environment, and its negative charge prevents passive diffusion across the negatively charged phospholipid bilayer of cells. Therefore, mRNA vaccines require a delivery vehicle. The current standard is the lipid nanoparticle (LNP).

LNPs are spherical structures typically 80–100 nm in diameter, composed of four lipid components: an ionizable cationic lipid, a phospholipid (often distearoylphosphatidylcholine, DSPC), cholesterol, and a polyethylene glycol (PEG)-lipid conjugate. The ionizable lipid is the critical component. At physiological pH (7.4), it is largely uncharged, minimizing toxicity in the bloodstream. However, within the acidic endosome (pH ~5.5–6.0), the lipid becomes protonated and positively charged. This charge promotes fusion with the endosomal membrane, facilitating the escape of mRNA into the cytosol—a process termed "endosomal escape." Without this escape, the mRNA would be degraded in the lysosome.

The mRNA itself is engineered for stability and translation efficiency. It contains a 5′ cap (typically a cap-1 structure, methylated at the 2′-O position of the first nucleotide), a 5′ untranslated region (UTR) derived from highly expressed genes (e.g., the α-globin or β-globin UTRs), a codon-optimized open reading frame (ORF) encoding the antigen, a 3′ UTR, and a poly(A) tail of 100–120 nucleotides. Additionally, the uridine residues are replaced with N1-methylpseudouridine. This modification serves two purposes: it evades recognition by innate immune sensors such as Toll-like receptor 3 (TLR3), TLR7, and TLR8, and retinoic acid-inducible gene I (RIG-I), thereby reducing inflammatory signaling; and it enhances translation efficiency by promoting ribosome processivity.

Antigen Production and Immune Activation

Once the LNP delivers the mRNA into the cytosol, the mRNA is recognized by ribosomes and translated into the antigen. For the SARS-CoV-2 mRNA vaccines (BNT162b2 and mRNA-1273), the antigen is the full-length spike glycoprotein, modified with two proline substitutions (K986P and V987P) to lock it in the prefusion conformation. This conformation is the metastable state that the virus uses to bind the ACE2 receptor, and presenting it in this form elicits neutralizing antibodies that recognize the receptor-binding domain (RBD).

The translated antigen is then processed through two major pathways:

MHC class I presentation: Endogenously synthesized proteins are ubiquitinated and degraded by the proteasome into 8–10 amino acid peptides. These peptides are transported into the endoplasmic reticulum (ER) via the transporter associated with antigen processing (TAP), where they load onto MHC class I molecules. The peptide–MHC I complex is trafficked to the cell surface, where it can be recognized by CD8+ cytotoxic T lymphocytes (CTLs). This is a critical advantage of mRNA vaccines: they mimic viral infection by producing antigen intracellularly, thus generating a robust CD8+ T-cell response.

MHC class II presentation: Some of the translated antigen is secreted or released upon cell death and taken up by professional antigen-presenting cells (APCs), particularly dendritic cells. These APCs process the antigen through the endosomal pathway, loading peptides onto MHC class II molecules for presentation to CD4+ helper T cells. CD4+ T cells, in turn, provide "help" to B cells, driving affinity maturation and class switching of antibodies.

The innate immune response is also engaged. The LNP itself acts as an adjuvant, though the mechanism is not fully defined. It is thought that LNPs activate the NLRP3 inflammasome in macrophages, leading to the release of IL-1β and IL-18, which promote local inflammation and recruitment of immune cells. Additionally, the N1-methylpseudouridine-modified mRNA, while not activating TLRs, may still engage the RNA sensor melanoma differentiation-associated protein 5 (MDA5) to a limited degree, providing a mild adjuvant effect without the toxicity of unmodified RNA.

Mechanism of Non-mRNA Vaccines

Non-mRNA vaccines encompass several distinct platforms, each with a different mechanism of antigen delivery and immune activation.

Inactivated and Live-Attenuated Vaccines

Inactivated vaccines consist of whole pathogens (viruses or bacteria) that have been killed or rendered non-infectious. Common methods of inactivation include treatment with formalin (e.g., the inactivated polio vaccine, IPV), β-propiolactone (used for some influenza vaccines), or heat. The pathogen's structural proteins remain intact, so the immune system recognizes them, but the pathogen cannot replicate. Inactivated vaccines are administered with an adjuvant (e.g., aluminum salts) to enhance immunogenicity. Antigen is presented primarily through the MHC class II pathway after uptake by APCs, generating a predominantly humoral (antibody) response with limited CD8+ T-cell activation.

Live-attenuated vaccines contain pathogens that have been weakened through serial passage in non-human cells or through targeted genetic mutation. Examples include the measles-mumps-rubella (MMR) vaccine, the oral polio vaccine (OPV), and the yellow fever vaccine (17D strain). These vaccines replicate in the host, producing a controlled, subclinical infection. Because the pathogen replicates, antigen is produced endogenously in infected cells, engaging both MHC class I and class II pathways. This generates robust humoral and cellular immunity, often lifelong after one or two doses. The trade-off is safety: live-attenuated vaccines are contraindicated in immunocompromised individuals because the attenuated pathogen can cause disease in the absence of a functional immune system.

Protein Subunit and Viral Vector Vaccines

Protein subunit vaccines deliver a purified antigen directly, without any genetic material. The antigen is produced recombinantly—for example, in yeast (Saccharomyces cerevisiae) for the hepatitis B surface antigen (HBsAg) or in insect cells via baculovirus expression for the influenza hemagglutinin protein. The antigen is formulated with an adjuvant, most commonly aluminum salts (alum) or the more potent AS01 (a liposome-based adjuvant containing MPL and QS-21, used in the Shingrix shingles vaccine). Subunit vaccines are extremely safe because they contain no infectious components, but they are weakly immunogenic without adjuvants and typically elicit a Th2-biased, antibody-dominated response with poor CD8+ T-cell activation.

Viral vector vaccines use a replication-incompetent virus (the vector) to deliver a gene encoding the antigen into host cells. The most widely used vectors are adenoviruses (e.g., human adenovirus type 26, Ad26, in the Johnson & Johnson COVID-19 vaccine; chimpanzee adenovirus, ChAdOx1, in the AstraZeneca vaccine) and modified vaccinia Ankara (MVA). The vector's genome is engineered to delete the E1 region (for Ad26) or other essential genes, rendering it unable to replicate. The antigen gene is inserted into this deleted region, under the control of a strong promoter such as the cytomegalovirus (CMV) immediate-early promoter.

Upon injection, the viral vector enters host cells (often muscle cells or APCs) via receptor-mediated endocytosis. The vector genome—but not the antigen gene—is transported to the nucleus, where it remains episomal (does not integrate into the host genome). The antigen gene is transcribed and translated in the cytosol, producing the antigen endogenously. This mimics viral infection and generates both MHC class I and class II responses, similar to mRNA vaccines. However, the vector itself is immunogenic, and pre-existing immunity to the vector (e.g., prior exposure to human adenovirus) can blunt the response. This is why chimpanzee adenoviruses or rare human serotypes are used.

Key Differences in Composition and Delivery

Lipid Nanoparticles vs. Adjuvants

The delivery systems for mRNA and non-mRNA vaccines are fundamentally different. mRNA vaccines rely on LNPs, which are complex formulations requiring precise ratios of four lipid components. The ionizable lipid (e.g., ALC-0315 in BNT162b2, SM-102 in mRNA-1273) is the active delivery agent. LNPs are produced by microfluidic mixing, where an ethanol phase containing the lipids is rapidly mixed with an aqueous phase containing the mRNA at a controlled flow rate, forming nanoparticles by self-assembly.

Non-mRNA vaccines use a variety of delivery systems. Inactivated and subunit vaccines are typically formulated with adjuvants—substances that enhance the immune response. Aluminum salts (alum) are the most common, adsorbing the antigen and creating a depot effect that prolongs antigen release and activates the NLRP3 inflammasome. More potent adjuvants include MF59 (an oil-in-water emulsion of squalene, used in influenza vaccines), AS03 (similar to MF59, used in pandemic influenza vaccines), and AS01 (a liposomal adjuvant containing monophosphoryl lipid A, MPL, and saponin QS-21). Viral vector vaccines do not require adjuvants because the vector itself provides intrinsic adjuvant activity through activation of innate immune sensors such as TLR9 (which recognizes CpG motifs in the vector DNA) and the cGAS-STING pathway.

Stability and Cold Chain Requirements

mRNA vaccines are notoriously unstable. The mRNA molecule is susceptible to hydrolysis, particularly at the 2′-OH group of ribose, and oxidation. LNPs can also fuse or aggregate over time. Consequently, mRNA vaccines require stringent cold-chain storage. BNT162b2 requires storage at −80 °C to −60 °C, while mRNA-1273 can be stored at −20 °C. Once thawed, both must be used within hours. This requirement is a major logistical challenge, particularly in low-resource settings.

Non-mRNA vaccines are generally more stable. Inactivated and subunit vaccines can be stored at 2–8 °C for months or years. Live-attenuated vaccines are more sensitive but can be lyophilized (freeze-dried) and reconstituted at the point of care; the MMR vaccine, for example, is stable for two years at 2–8 °C after lyophilization. Viral vector vaccines, such as the AstraZeneca COVID-19 vaccine, can be stored at 2–8 °C for up to six months. The table below summarizes these differences.

Property	mRNA Vaccines	Inactivated/Subunit Vaccines	Viral Vector Vaccines
Antigen source	Host-cell translation of delivered mRNA	Purified protein or inactivated pathogen	Host-cell translation of vector-encoded gene
Delivery vehicle	Lipid nanoparticle	Adjuvant (alum, MF59, AS01)	Replication-incompetent virus
Storage temperature	−80 °C to −20 °C	2–8 °C	2–8 °C
MHC class I activation	Yes (endogenous synthesis)	Minimal (exogenous antigen)	Yes (endogenous synthesis)
MHC class II activation	Yes	Yes	Yes
Adjuvant requirement	No (LNP is intrinsic adjuvant)	Yes	No (vector is intrinsic adjuvant)
Manufacturing speed	Very fast (cell-free)	Slow (requires cell culture or fermentation)	Moderate (requires cell culture)

Immune Response and Efficacy

Antibody Production

Both mRNA and non-mRNA vaccines elicit neutralizing antibodies, but the kinetics and magnitude differ. mRNA vaccines, particularly the SARS-CoV-2 vaccines, generate high titers of neutralizing antibodies after two doses. The prefusion-stabilized spike protein is highly immunogenic, and the LNP delivery ensures efficient antigen presentation in draining lymph nodes. Antibody titers peak at 2–4 weeks after the second dose and decline over several months, necessitating booster doses.

Inactivated vaccines, such as the inactivated polio vaccine, also elicit neutralizing antibodies, but the response is often weaker and shorter-lived than that of live-attenuated vaccines. This is because inactivated pathogens do not replicate, so the antigen dose is fixed and cannot amplify. Protein subunit vaccines, such as the hepatitis B vaccine, require three doses to achieve protective antibody titers (>10 mIU/mL for HBsAg), with the third dose serving as a booster.

Live-attenuated vaccines generate the most durable antibody responses. The measles vaccine, for example, produces antibody titers that persist for decades, likely due to the sustained antigen exposure from viral replication and the establishment of long-lived plasma cells in the bone marrow.

T-Cell Activation

The most significant immunological difference between mRNA and non-mRNA vaccines is the magnitude of the CD8+ T-cell response. mRNA vaccines and viral vector vaccines produce antigen endogenously, loading peptides onto MHC class I molecules and activating CD8+ cytotoxic T cells. This is critical for clearing intracellular pathogens and for eliminating virus-infected cells.

Inactivated and subunit vaccines, by contrast, deliver exogenous antigen that is processed through the MHC class II pathway, activating CD4+ helper T cells but not CD8+ T cells. This is a fundamental limitation of these platforms. However, some adjuvants can partially overcome this. For example, the AS01 adjuvant in the Shingrix vaccine promotes a modest CD8+ T-cell response by activating dendritic cells through the TLR4 agonist MPL and the STING pathway agonist QS-21.

The CD4+ T-cell response also differs. mRNA vaccines elicit a Th1-biased response, characterized by interferon-gamma (IFN-γ) production, which supports cellular immunity. Aluminum-adjuvanted vaccines elicit a Th2-biased response, characterized by IL-4 and IL-5 production, which supports humoral immunity but is less effective against intracellular pathogens.

Safety and Side Effects

Common Reactions

Both vaccine types cause local and systemic reactions, but the profile differs. mRNA vaccines commonly cause injection-site pain, redness, and swelling, as well as systemic symptoms such as fatigue, headache, myalgia, and fever. These reactions are more pronounced after the second dose and are more common in younger individuals. The mechanism is the potent innate immune activation by the LNP and the mRNA, which triggers a strong inflammatory cytokine response (IL-6, TNF-α, IFN-γ).

Inactivated and subunit vaccines also cause local reactions, but systemic symptoms are generally milder. Aluminum-adjuvanted vaccines can cause granulomas at the injection site, a delayed-type hypersensitivity reaction. Live-attenuated vaccines can cause a mild, self-limited form of the disease; for example, the MMR vaccine can cause a transient rash and low-grade fever 7–12 days after vaccination.

Rare Adverse Events

mRNA vaccines have been associated with rare cases of myocarditis and pericarditis, particularly in young males aged 16–30 within a week of the second dose. The incidence is approximately 1–5 per 100,000 vaccinated individuals. The mechanism is not fully understood but may involve molecular mimicry between the spike protein and cardiac myosin, or an exaggerated inflammatory response in the heart.

Viral vector vaccines (AstraZeneca, Johnson & Johnson) have been associated with vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but serious condition characterized by thrombosis at unusual sites (cerebral venous sinus, splanchnic veins) and thrombocytopenia. VITT is caused by antibodies against platelet factor 4 (PF4), which activate platelets and cause clot formation. The incidence is approximately 1 per 50,000–100,000 doses.

Inactivated and subunit vaccines have a very low rate of serious adverse events. The most notable is anaphylaxis, which occurs at a rate of approximately 1 per million doses for most vaccines. Live-attenuated vaccines are contraindicated in pregnancy and in severely immunocompromised individuals because the attenuated pathogen can cause disseminated disease.

Development and Manufacturing

Speed of Development

mRNA vaccines have a transformative advantage in development speed. Once the antigen sequence is known, the mRNA can be synthesized in a cell-free system within days. The entire process—sequence design, codon optimization, N1-methylpseudouridine incorporation, LNP formulation, and quality control—can be completed in 3–4 weeks. This was demonstrated during the COVID-19 pandemic, where the first mRNA vaccine candidate entered clinical trials just 63 days after the SARS-CoV-2 genome was published.

Non-mRNA vaccines are slower to develop. Inactivated vaccines require growing the pathogen in large quantities (e.g., in embryonated chicken eggs for influenza or in Vero cells for polio), then inactivating and purifying it. This process takes 4–6 months. Protein subunit vaccines require cloning the antigen gene into an expression vector, transfecting a host cell line (yeast, CHO cells, insect cells), establishing a stable cell line, and developing a purification process—a timeline of 6–12 months. Viral vector vaccines are faster than subunit vaccines but still require cell culture and vector production, typically taking 3–6 months.

Manufacturing Complexity

mRNA vaccine manufacturing is cell-free and scalable. The process involves in vitro transcription (IVT) using a bacteriophage RNA polymerase (T7 or SP6), a linearized DNA template, ribonucleotide triphosphates (including N1-methylpseudouridine triphosphate), and a cap analog. The reaction is performed in a buffer containing magnesium chloride (typically 20–40 mM), dithiothreitol (DTT) as a reducing agent, and inorganic pyrophosphatase to prevent pyrophosphate inhibition. After IVT, the mRNA is purified by oligo(dT) affinity chromatography and then formulated into LNPs by microfluidic mixing. The entire process is continuous and can be scaled by increasing reactor volume or parallelizing mixing lines.

Non-mRNA vaccine manufacturing is more complex and requires biological systems. Inactivated vaccines require large-scale cell culture (e.g., MDCK cells for influenza) or egg-based production, followed by concentration, inactivation, and purification. Subunit vaccines require fermentation (for yeast) or cell culture (for mammalian cells), followed by multiple chromatography steps (affinity, ion exchange, size exclusion) to achieve purity. Viral vector vaccines require transfection of producer cells (e.g., HEK293 cells) with the vector genome and helper plasmids, followed by cell lysis, clarification, and purification by ultracentrifugation or chromatography. These processes are batch-based and difficult to scale rapidly.

Common Misconceptions and Pitfalls

mRNA Does Not Alter DNA

A persistent misconception is that mRNA vaccines integrate into the host genome or alter DNA. This is mechanistically impossible. mRNA is a single-stranded RNA molecule that acts as a transient messenger. It never enters the nucleus, and there is no reverse transcriptase in human cells to convert it into DNA. The mRNA is translated in the cytosol and then degraded by RNases within hours to days. The difference between epigenetic and genetic changes is relevant here: mRNA vaccines cause neither. They do not modify the sequence of genomic DNA, nor do they alter epigenetic marks such as DNA methylation or histone modification.

The confusion likely arises from conflating mRNA vaccines with viral vector vaccines or with gene therapy. Viral vector vaccines deliver DNA into the nucleus, but the vector genome is engineered to be episomal—it does not integrate. Gene therapy vectors (e.g., adeno-associated virus, AAV) can integrate at low frequencies, but this is a different technology. For a deeper understanding of how gene expression is regulated, see the difference between enhancer and promoter.

Non-mRNA Vaccines Are Not Obsolete

The success of mRNA vaccines during the COVID-19 pandemic has led some students to assume that non-mRNA vaccines are outdated. This is incorrect. Non-mRNA vaccines remain essential for several reasons. First, they are more stable and do not require ultra-cold storage, making them more suitable for global distribution. Second, they have a longer track record of safety. Third, some pathogens are not amenable to mRNA vaccine approaches. For example, polysaccharide antigens (e.g., from Streptococcus pneumoniae or Neisseria meningitidis) cannot be encoded by mRNA because they are not proteins. Conjugate vaccines, which link polysaccharides to carrier proteins, remain the only effective approach for these pathogens.

Additionally, mRNA vaccines have not yet been successfully developed for many diseases. The technology is highly effective for viral surface glycoproteins but has struggled with bacterial antigens, parasitic antigens, and cancer neoantigens. Non-mRNA platforms, particularly protein subunit vaccines, remain the workhorse for these applications.

mRNA Vaccines Do Not Cause Autoimmune Diseases

Another misconception is that mRNA vaccines trigger autoimmune diseases by causing the immune system to attack self-tissues. While mRNA vaccines do elicit strong inflammatory responses, there is no evidence that they cause autoimmune disease at a rate higher than the background incidence. The rare cases of myocarditis are not autoimmune in origin but rather an inflammatory response in the heart muscle. The distinction is important: inflammation is a normal, transient response to vaccination, whereas autoimmunity involves persistent self-reactivity mediated by autoreactive T cells or autoantibodies.

Summary and Practical Takeaways

The fundamental difference between mRNA and non-mRNA vaccines is the source of the antigen. mRNA vaccines deliver genetic instructions that the host cell translates into antigen, mimicking a viral infection and generating both humoral and cellular immunity. Non-mRNA vaccines deliver the antigen directly (inactivated, subunit) or via a viral vector that produces the antigen in host cells. The choice of platform affects every aspect of the vaccine, from storage requirements to the type of immune response elicited.

For exam preparation, focus on the following points:

mRNA vaccines use LNPs for delivery; the mRNA is modified with N1-methylpseudouridine to reduce innate immune activation and enhance translation.
mRNA vaccines activate both MHC class I and class II pathways, generating CD8+ and CD4+ T-cell responses.
Inactivated and subunit vaccines activate only the MHC class II pathway, generating a predominantly humoral response.
Live-attenuated vaccines replicate in the host, providing sustained antigen exposure and durable immunity.
Viral vector vaccines deliver DNA to the nucleus but do not integrate; they generate both cellular and humoral immunity.
mRNA vaccines require ultra-cold storage; non-mRNA vaccines are generally stable at 2–8 °C.
mRNA vaccines can be developed and manufactured much faster than non-mRNA vaccines.

Frequently Asked Questions

What is the main difference between mRNA and non-mRNA vaccines?

The main difference is the source of the antigen. mRNA vaccines deliver messenger RNA that instructs the recipient's cells to produce the antigen. Non-mRNA vaccines deliver the antigen directly (inactivated or subunit vaccines) or use a viral vector to deliver a gene encoding the antigen. This difference affects the type of immune response, storage requirements, and manufacturing speed.

Do mRNA vaccines alter your DNA?

No. mRNA vaccines deliver RNA that is translated in the cytosol and then degraded. The mRNA never enters the nucleus, and human cells lack the reverse transcriptase enzyme needed to convert RNA into DNA. There is no mechanism by which mRNA vaccines can integrate into the genome or cause permanent genetic changes.

Are mRNA vaccines more effective than non-mRNA vaccines?

Not universally. mRNA vaccines are highly effective for certain pathogens, particularly viruses with surface glycoproteins like SARS-CoV-2. However, non-mRNA vaccines remain more effective for other applications, such as polysaccharide antigens (pneumococcus, meningococcus) and for generating long-lived antibody responses (live-attenuated vaccines). Efficacy depends on the pathogen, the antigen, and the immune response required for protection.

What are examples of non-mRNA vaccines?

Examples include the inactivated polio vaccine (IPV), the measles-mumps-rubella (MMR) vaccine (live-attenuated), the hepatitis B vaccine (protein subunit), the shingles vaccine Shingrix (protein subunit with AS01 adjuvant), and the AstraZeneca and Johnson & Johnson COVID-19 vaccines (viral vector).

Why do mRNA vaccines require cold storage?

mRNA is chemically unstable. The 2′-hydroxyl group of ribose makes the RNA backbone susceptible to hydrolysis, particularly at elevated temperatures. Additionally, the lipid nanoparticles can fuse or degrade over time. Ultra-cold storage (−80 °C to −20 °C) slows these degradation processes, preserving the integrity of the mRNA and the LNP structure.

How do mRNA vaccines work?

mRNA vaccines deliver lipid nanoparticle-encapsulated mRNA encoding the antigen. The LNP fuses with the endosomal membrane, releasing the mRNA into the cytosol. Ribosomes translate the mRNA into the antigen, which is processed and presented on MHC class I and class II molecules. This activates CD8+ cytotoxic T cells, CD4+ helper T cells, and B cells, generating both cellular and humoral immunity.

What are the side effects of mRNA vaccines?

Common side effects include injection-site pain, redness, swelling, fatigue, headache, myalgia, and fever. These are typically mild and resolve within 1–3 days. Rare adverse events include myocarditis and pericarditis, particularly in young males after the second dose. Anaphylaxis is extremely rare, occurring in approximately 1 per 100,000–1,000,000 doses.

Key Takeaways

mRNA vaccines deliver genetic instructions for antigen production; non-mRNA vaccines deliver the antigen itself or a viral vector encoding it.
mRNA vaccines activate both MHC class I and class II pathways, generating CD8+ and CD4+ T-cell responses; inactivated and subunit vaccines primarily activate the MHC class II pathway.
mRNA vaccines require ultra-cold storage due to RNA instability; most non-mRNA vaccines are stable at 2–8 °C.
mRNA vaccines can be developed and manufactured in weeks, whereas non-mRNA vaccines take months.
mRNA vaccines do not integrate into or alter genomic DNA; they are transient and degraded after translation.
Non-mRNA vaccines remain essential for many pathogens, particularly those with non-protein antigens.
The choice of vaccine platform is determined by the pathogen, the required immune response, and logistical considerations such as storage and distribution capacity.